Amneal Pharmaceuticals Inc (NYSE:AMRX) has received an average rating of “Hold” from the thirteen brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $16.00.
A number of analysts have recently commented on the company. SunTrust Banks assumed coverage on Amneal Pharmaceuticals in a research report on Tuesday, March 19th. They issued a “buy” rating and a $16.00 price target on the stock. ValuEngine cut Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, April 5th. Zacks Investment Research raised Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Cantor Fitzgerald reissued a “buy” rating and issued a $35.00 price target on shares of Amneal Pharmaceuticals in a research report on Thursday, February 28th. Finally, Leerink Swann cut Amneal Pharmaceuticals to a “market perform” rating in a research report on Friday, March 8th.
Amneal Pharmaceuticals stock opened at $7.32 on Thursday. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44. The company has a market cap of $2.28 billion, a price-to-earnings ratio of 7.71, a PEG ratio of 0.47 and a beta of 1.64. Amneal Pharmaceuticals has a fifty-two week low of $7.19 and a fifty-two week high of $24.48.
Amneal Pharmaceuticals (NYSE:AMRX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The firm had revenue of $446.00 million for the quarter, compared to the consensus estimate of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. As a group, analysts forecast that Amneal Pharmaceuticals will post 0.91 earnings per share for the current year.
In related news, VP Andrew S. Boyer purchased 19,000 shares of the company’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $9.46 per share, with a total value of $179,740.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Pradeep Bhadauria purchased 7,000 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average cost of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. Over the last three months, insiders bought 41,000 shares of company stock worth $387,300. Insiders own 26.34% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Menta Capital LLC bought a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $403,000. SG Americas Securities LLC bought a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $192,000. Meeder Asset Management Inc. lifted its position in Amneal Pharmaceuticals by 785.6% in the 1st quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares in the last quarter. Norges Bank bought a new position in Amneal Pharmaceuticals in the 4th quarter valued at approximately $18,243,000. Finally, Principal Financial Group Inc. lifted its position in Amneal Pharmaceuticals by 30.4% in the 4th quarter. Principal Financial Group Inc. now owns 16,485 shares of the company’s stock valued at $223,000 after acquiring an additional 3,843 shares in the last quarter. 36.05% of the stock is currently owned by institutional investors and hedge funds.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.